Effect of Compound Amino Acid Tablets on Nutritional Status of Patients With Lung Cancer

Lung Cancer Clinical Trial

Official title:

Effect of Compound Amino Acid Tablets on Nutritional Status of Patients With Lung Cancer

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05770063
• Other study ID #: YNLX-2022-011
• Status: Not yet recruiting
• Phase: N/A
• Start date: April 15, 2023
• Est. completion date: August 30, 2023

Study information

• Verified date: March 2023
• Source: Beijing Chest Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To investigate whether compound amino acid supplementation can further promote protein synthesis and improve nutritional status for lung cancer patients.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 86
• Est. completion date: August 30, 2023
• Est. primary completion date: July 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• NRS2002 >=3 scores
• lung cancer patients
• low albumin or hemoglobin
• informed consent

Exclusion Criteria:

• Acute and critical patients;
• Severe liver and kidney dysfunction;
• Patients with gastrointestinal bleeding or intestinal obstruction;
• Pregnant women, lactating women, people with mental illness, and people without independent behavior ability.

Related Conditions & MeSH terms

• Amino Acid Deficiency
• Lung Cancer
• Lung Neoplasms
• Malnutrition

Intervention

Dietary Supplement:
• amino acid tablet
multiple essential amino acids supplements

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Beijing Chest Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Concentration of albumin		after 42 days after the intervention